
Strides Shasun receives USFDA approval for Oseltamivir Phosphate Capsules

Products to be marketed by Strides Pharma Inc. in the US Market

Bangalore, June 11, 2018 Strides Shasun Limited today announced that it's wholly owned subsidiary Strides Pharma Global Pte. Ltd. has received final approval for ***Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base)*** from the United States Food & Drug Administration (US FDA). Oseltamivir Phosphate Capsules is a generic version of Tamiflu Capsules of Hoffmann-La Roche, Inc.

Oseltamivir Phosphate Capsules registered a significant volume growth due to one of the worst flu seasons in the US last year. As per IQVIA MAT April 2018 data, the US market for Oseltamivir Phosphate Capsules was approximately USD 725 Million. The product will be manufactured at the company's Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market.

The company has 75 cumulative ANDA filings with USFDA of which 48 ANDAs have been approved as of date and 27 are pending approval.

About Oseltamivir Phosphate Capsule

Oseltamivir Phosphate Capsule is prescribed to treat symptoms caused by the flu virus (influenza). It helps make the symptoms such as stuffy nose, cough, sore throat, fever/chills, aches, and tiredness less severe and shortens the recovery time.

About Strides Shasun

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is global pharmaceutical Company headquartered in Bangalore. The Company has two business verticals, viz., Regulated Markets and Emerging Markets.

The Company has global manufacturing footprint with 7 manufacturing facilities spread across three continents including 5 US FDA approved facilities and 2 facilities for the emerging markets. The Company has strong R&D infrastructure in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

<p><u>Strides</u></p> <p>Badree Komandur, Executive Director +91 80 6784 0747</p> <p><u>Investors:</u></p> <p>Kannan. N: +91 98450 54745 Vikesh Kumar: +91 80 6784 0827 Sandeep Baid : +91 80 6784 0791</p> <p>Strides Shasun Limited CIN : L24230MH1990PLC057062 Regd. Office: 201, 'Devavrata', Sector – 17, Vashi, Navi Mumbai – 400 703 Email: investors@stridesshasun.com</p>	<p><u>PR Consultancy</u></p> <p>Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com</p> <p>K Priya: +91 9535425418 priya@fortunapr.com</p>
---	--